VIROGIN BIOTECH
Virogin Biotech Ltd. ("Virogin") was founded in 2015, with the headquarters located in Vancouver, Canada. They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlyticโข technical platform for improved cancer treatment. By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.
VIROGIN BIOTECH
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.virogin.com
Total Employee:
11+
Status:
Active
Contact:
+86 (755) 33122597
Email Addresses:
[email protected]
Total Funding:
204 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Domain Not Resolving Microsoft Exchange Online Organization Schema Office 365 Mail
Current Advisors List
Current Employees Featured
Founder
Investors List
China Life Healthcare Fund
China Life Healthcare Fund investment in Series D - Virogin Biotech
CDH Investments
CDH Investments investment in Series C - Virogin Biotech
Shenzhen Xiaoxi Holdings
Shenzhen Xiaoxi Holdings investment in Series C - Virogin Biotech
China Merchants Capital
China Merchants Capital investment in Series C - Virogin Biotech
Korea Investment Partners
Korea Investment Partners investment in Series C - Virogin Biotech
CMG-SDIC Capital Management
CMG-SDIC Capital Management investment in Series C - Virogin Biotech
Peking University Mingde Fund
Peking University Mingde Fund investment in Series C - Virogin Biotech
Pan-Lin Capital
Pan-Lin Capital investment in Series C - Virogin Biotech
Purity Star
Purity Star investment in Series B - Virogin Biotech
Borun Capital
Borun Capital investment in Series B - Virogin Biotech
Official Site Inspections
http://www.virogin.com Semrush global rank: 6.63 M Semrush visits lastest month: 914
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Virogin Biotech" on Search Engine
Virogin Biotech
Virogin Biotech is a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have developed two platforms: (1) innovative HSV-1 based oncolytic virus and (2) mRNA-based (including self-amplifying RNA/saRNA) therapeutics , aiming to elicit robust and durable anti-tumor immune response against โฆSee details»
About - Virogin
Founded in Canada in 2015, Virogin aims to unleash synergy between oncolytic virotherapy and mRNA vaccines in the battle against cancer. Our vision is to be a global, best-in-class immuno-oncology company that creates impactful โฆSee details»
Virogin Biotech - Crunchbase Company Profile & Funding
Virogin Biotech Ltd. ("Virogin") was founded in 2015, with the headquarters located in Vancouver, Canada. They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlyticโข โฆSee details»
Virogin Biotech
Virogin Biotech Ltd is dedicated to new oncolytic virus therapeutics using our TTDR oncolytic virus platform, while exploring new innovative immunotherapy ideas.See details»
Virogin Biotech | LinkedIn
Virogin Biotech | 7,427 followers on LinkedIn. Virotherapy to Ignite Immunotherapy | Virogin Biotech aims to be a global, best-in-class oncolytic virus company that creates impactful drugs...See details»
Pipeline - Virogin
Virogin is dedicated to bringing next-generation immuno-oncology therapeutics to the clinic through our robust pipeline. Oncolytic Virus (Attenuated & Non-attenuated Viral Backbone๏ผ Backbone. ID# Indications. PHASE. Discovery. IND-Enabling. Phase III. Commercial. Virogin rights. Attenuated. VG161* (I.T) HCC, ICC, etc.See details»
Virogin Biotech Receives IND Approvals from Chinese NMPA for โฆ
Jun 17, 2022 Vancouver, Canada โ Virogin Biotech, a clinical-stage biotech company, is pleased to announce that, on April 19, 2022, the National Medical Products Administration (NMPA), the Chinese agency for regulating drugs and medical devices, granted IND approvals for the companyโs investigational drug candidates VG201 and VG161, allowing โฆSee details»
News - Virogin
Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors Virogin Biotech Receives IND Approval from the U.S. FDA for VG201 Virogin Biotech Receives IND Approvals from Chinese NMPA for VG201 and VG161See details»
Virogin Biotech Receives IND Approval from the U.S. FDA for โฆ
August 12, 2022. Vancouver, Canada โ Virogin Biotech, a clinical-stage biotech company is pleased to announce that their Investigational New Drug (IND) application for VG201 has been granted by the U.S. Food and Drug Administration (FDA), allowing Virogin to initiate a Phase I clinical trial of VG201.See details»
Virogin Biotech and MD Anderson Announce Strategic
Sep 8, 2022 VANCOUVER, British Columbia & HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center today...See details»
Virogin Biotech Announces Closing of $127 Million in Series D2 ...
December 15, 2021. ViroGin Biotech Canada Ltd. VANCOUVER, BC & SHANGHAI- Virogin Biotech is pleased to announce the closing of its Series D2 round of financing, raising $127 million USD. The financing round was led by China Life Healthcare, with participation from Shenzhen Capital Group, CMB International Capital, China Capital โฆSee details»
Virogin Biotech Announces Dosing the First US Patient in a โฆ
Nov 15, 2022 The trial is part of an ongoing strategic collaboration between Virogin and MD Anderson. About Virogin Biotech: Virogin Biotech is a clinical-stage biotech company developing next-generation immuno-oncolytic therapeutics to enhance systemic anti โฆSee details»
Virogin Biotech to Form a Joint Venture with Chinaโs Largest ...
Vancouver, Canada โ Virogin Biotech (โViroginโ) is pleased to announce it has recently signed an agreement with China National Biotec Group (CNBG) to create a Joint Venture that will focus on the research & development, clinical development, and commercialization of oncolytic virotherapies.See details»
Virogin Biotech and MD Anderson Announce Strategic โฆ
Sep 8, 2022 VANCOUVER, BC & HOUSTON, TX โ Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced โฆSee details»
MD Anderson and Virogin Biotech announce strategic โฆ
Sep 7, 2022 Newswise โ HOUSTON and VANCOUVER, Canada โ The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of...See details»
Virogin Biotech Company Profile 2024: Valuation, Funding
Virogin Biotech Overview. Update this profile. Year Founded. 2015. Status. Private. Employees. 170. Latest Deal Type. Series D2. Latest Deal Amount. $127M. Investors. 26. General Information. Description. Developer of oncolytic virus technology designed to treat tumors and inhibit tumor growth.See details»
VIROGIN Receives FDA Fast Track Designation for VG161, a โฆ
July 13, 2023. ViroGin Biotech Canada Ltd. VANCOUVER, BC โ Virogin Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of VG161 for patients with advanced unresectable Hepatocellular Carcinoma.See details»
Virogin Biotech - Funding, Financials, Valuation & Investors
Virogin Biotech is funded by 18 investors. China Life Healthcare Fund and CDH Investments are the most recent investors. Unlock for free. Funding Rounds. Number of Funding Rounds 7. Total Funding Amount. Unlock for free. Virogin Biotech has raised a total of. $204M. in funding over 7 rounds.See details»
Virogin Biotech Company Profile - Office Locations, Competitors โฆ
Virogin Biotech is a company that specializes in oncolytic virotherapy. Its platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a transient antiviral immune response through synergy with multiple payload expression. Type. Private. Status. Active. Founded. 2015. HQ. Vancouver, CA | view all locations. site.See details»
Virogin Biotech Receives IND Approval from the U.S. FDA for โฆ
Feb 3, 2022 VANCOUVER, B.C. โ Virogin Biotech, a clinical-stage biotech company is pleased to announce that their Investigational New Drug (IND) application for VG201 has been granted by the U.S. Food and Drug Administration (FDA), allowing Virogin to initiate a Phase I clinical trial of VG201.See details»